Definitive Healthcare Q2 Revenue Falls 9%, Goodwill Fully Impaired, Nasdaq Delisting Looms
DH is trading near its 52-week low of $0.62 (13% above the low).
Summary
Definitive Healthcare reported Q2 2026 revenue of $55.2M, down 9% YoY, with a net loss of $7.5M. Goodwill is fully impaired, and the company faces a Nasdaq delisting deadline of December 15, 2026.
Key Events · Earnings and Guidance · DH
-
Revenue Decline Accelerates
Q2 2026 revenue fell 9% YoY to $55.2M, missing the $55.48M consensus. Subscription revenue dropped to $52.8M from $58.2M a year ago.
-
Goodwill Fully Impaired
A $197.2M non-cash goodwill impairment charge in Q1 2026 reduced goodwill to $0, reflecting sustained stock price declines and a market cap below book value.
-
Nasdaq Delisting Notice
Received June 18, 2026, for failing to maintain a $1.00 minimum bid price. The company has until December 15, 2026, to regain compliance or face delisting.
-
Cost Cutting and Restructuring
A restructuring plan reduced headcount by ~40 employees, incurring $1.1M in charges. Operating expenses declined 7% YoY in Q2, partially offsetting revenue weakness.
Analysis · DH · Technology
Definitive Healthcare's Q2 2026 results show a 9% revenue decline to $55.2M, missing consensus, and a net loss of $7.5M. The company fully impaired its remaining goodwill, leaving none on the balance sheet. A Nasdaq delisting notice adds urgency, with a December 15, 2026 deadline to regain compliance. While adjusted EBITDA of $14.6M and $170.9M in cash provide some runway, the combination of declining revenue, a sub-$1 stock price, and the delisting threat creates significant uncertainty for shareholders.
At the time of this filing, DH was trading at $0.70 on NASDAQ in the Technology sector, with a market capitalization of approximately $100.4M. The 52-week trading range was $0.62 to $4.70. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.